2415 results about "Diketone" patented technology

The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and / or metastasis of prostate cancer cells.

As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency which achieves improved color purity by a reduction of half width of an emission spectrum is provided. One embodiment of the present invention is an organometallic complex in which a β-diketone and a six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom are ligands. In General Formula (G1), X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, R1 to R4 each represent a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.

The thin film-forming material of the present invention comprises a bis(β-diketonato)zinc compound that is liquid at 25° C. and is suitable for forming a zinc-containing thin film. By using the thin film-forming material, a thin film can be produced with stable film-forming rate or stable film composition control without suffering from problems of raw material gas suppliability and in-line raw material transport. Preferred (β-diketonato)zinc compounds include, for example, bis(octane-2,4-dionato)zinc and bis(2,2-dimethyl-6-ethyldecane-3,5-dionato)zinc.

A method of forming a single-metal film on a substrate by plasma ALD includes: contacting a surface of a substrate with a β-diketone metal complex in a gas phase; exposing molecule-attached surface to a nitrogen-hydrogen mixed plasma; and repeating the above steps, thereby accumulating atomic layers to form a single-metal film on the substrate.

The present invention provides bioactive polymer compositions that can be formulated to release a wound healing agent at a controlled rate by adjusting the various components of the composition. The composition can be used in an external wound dressing, as a polymer implant for delivery of the wound healing agent to an internal body site, or as a coating on the surface of an implantable surgical device to deliver wound healing agents that are covalently attached to a biocompatible, biodegradable polymer and / or embedded within a hydrogel. Methods of using the invention bioactive polymer compositions to promote natural healing of wounds, especially chronic wounds, are also provided. Examples of biodegradable copolymer polyesters useful in forming the blood-compatible, hydrophilic layer or coating include copolyester amides, copolyester urethanes, glycolide-lactide copolymers, glycolide-caprolactone copolymers, poly-3-hydroxy butyrate-valerate copolymers, and copolymers of the cyclic diester monomer, 3-(S)[(alkyloxycarbonyl)methyl]-1,4-dioxane-2,5-dione, with L-lactide. The glycolide-lactide copolymers include poly(glycolide-L-lactide) copolymers formed utilizing a monomer mole ratio of glycolic acid to L-lactic acid ranging from 5:95 to 95:5 and preferably a monomer mole ratio of glycolic acid to L-lactic acid ranging from 45:65 to 95:5. The glycolide-caprolactone copolymers include glycolide and ε-caprolactone block copolymer, e.g., Monocryl or Poliglecaprone.

Metal-oxide films for lithographic applications are provided. The films are formed from compositions comprising metal-oxide precursor compounds including metals and metalloids other than silicon. These films are easily produced and can be modified with a variety of ligands, including alkoxides, phenoxides, carboxylates, beta-diketones, and beta-ketoesters.

Benzodiazepinc compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures (I) or (II): wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.

A process for preparing 1-hexene which comprises trimerizing ethylene in a 1-hexene solvent in the presence of a catalyst system prepared by contacting in a 1-hexene solvent the following components (A), (B), (C) and (D):(A) a chromium-containing compound represented by the general formula: CrXkYm wherein X is a residue of a carboxylic acid, a residue of a 1,3-diketone, a halogen atom or an alkoxyl group, k is an integer of 2 to 4, Y in Ym is an amine compound, a phosphine compound, a phosphine oxide compound, a nitrosyl group or an ether compound and m is an integer of 0 to 6, with the proviso that any two Y's may be same or different;(B) trialkylaluminum or dialkylaluminum hydride;(C) a pyrrole compound or a derivative thereof;(D) a group 13 (IIIB)-halogen compound represented by the general formula: MTtU3-t or a group 14 (IVB)-halogen compound represented by the general formula: M'Tt'U4-t' wherein M is an atom from the group 13 (IIIB), M' is an atom from the group 14(IVB), T is an alkyl group, an aryl group, an allyl group or a hydrogen atom, U is a halogen atom, t is a real number of 0 or more and less than 3 and t' is a real number of 0 or more and less than 4.

The concentrates comprise specified proportions of diluent oil, an organic sulfur-containing antiwear and / or extreme pressure agent, an ashless dispersant, a dimethyl ester of an aliphatic phosphonic acid in which the aliphatic group has an average in the range of about 12 to about 24 carbon atoms, and a 3-hydrocarbyl-2,5-diketopyrrolidine in which the hydrocarbyl group is an alkyl or alkenyl group having an average in the range of about 12 to about 30 carbon atoms. By using weight ratios of diketopyrrolidine to the dimethyl phosphonate of at least 3:1, the concentrate remains homogeneous at temperatures at least as low as 12 DEG C. When utilized as a top treat in gear oils formulated with conventional GL-4 and GL-5 gear additive packages substantial improvements in limited slip axle performance can be realized.

A coating composition is provided comprising a) an aqueous dispersion, having a pH of less than 7.5, of silica nanoparticles having average particle diameters of 40 nanometers or less, b) an alkoxysilane oligomer; c) a silane coupling agent, and d) optionally a metal β-diketone complexing agent. The compositions may be used to prepare coated articles wherein the coating is substantially uniform in thickness, durably adheres to the substrate, and provides hydrophilic and / or antireflection surface properties to the substrate.

The present invention relates to a new industrial process for the synthesis of solvate- free 17a-acetoxy-11ss-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent. The invention also relates to compounds of formula (VII) and (VIII) used as intermediates in the process. The process according to the invention is the following: i) 3-(ethylene-dioxy)-estra-5(10),9(11)-diene-17-one of formula (X) is reacted with potassium acetilyde formed in situ in dry tetrahydrofuran by known method, ii) the obtained 3-(ethylene-dioxy)-17a-ethynyl-17ss-hydroxy-estra-5(10),9(11)-diene of formula (IX) is reacted with phenylsulfenyl chloride in dichloromethane in the presence of triethylamine and acetic acid, iii) the obtained isomeric mixture of 3-(ethylene-dioxy)-21-(phenyl-sulfinyl)-19-norpregna-5(10),9(11),17(20),20-tetraene of formula (VIII) is reacted first with sodium methoxide in methanol, then with trimethyl phosphite, iv) the obtained 3-(ethylene-dioxy)-17a-hydroxy-20-methoxy-19-norpregna-5(10),9(11),20-triene of formula (VII) is reacted with hydrogen chloride in methanol, then v) the obtained 3-(ethylene-dioxy)-17a-hydroxy-19-norpregna-5(10),9(11l); -diene-20- one of formula (VI) is reacted with ethylene glycol hi dichloromethane in the presence of trimethyl orthoformate and p-toluenesulfonic acid by known method, vi) the obtained 3,3,20,20-bis(ethylene-dioxy)-17a-hydroxy-19-norpregna- 5(10),9(11)-diene of formula (V) is reacted with hydrogen peroxide in a mixture of pyridine and dichloromethane in the presence of hexachloroacetone by known method, vii) the obtained 3,3,20,20-bis(ethylene-dioxy)-17a-hydroxy-5,10-epoxy-19-norpregn-9(11)-ene of formula (IV), containing approximately a 1:1 mixture of 5a,10a- and 5ss,10ss-epoxides, is isolated from the solution and reacted with a Grignard reagent obtained from 4-bromo-N,N-dimethyl-aniline in tetrahydrofuran.

The invention discloses a powdery calcium-zinc complex heat stabilizer, which comprises the following components in weight ratio: 20-30 parts of zinc stearate, 15-25 parts of calcium stearate, 4-8 parts of epoxy compound, 15-25 parts of beta-diketone, 2-6 parts of antioxidant, 10-15 parts of polyatomic alcohol, 12-16 parts of inorganic assistant and 10-15 parts of lubricant. The powdery calcium-zinc complex heat stabilizer disclosed by the invention is capable of effectively delaying the generation of zinc-burning phenomenon of a system and improving the initial-stage and long-term heat stability of polyvinyl chloride (PVC), and moreover, the system has a good lubrication component, thus, the dispersion property and the processing property of the system in resin can be improved, thereby being beneficial to reducing energy consumption.

This disclosure relates to amides, aryl sulphonamides, aryl ureas, and α,β-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing these compounds, and to methods for treating or ameliorating the toxic effects following administration of drugs such as cancer therapy drugs, treating or ameliorating the effects of a drug overdose, and to the use of the compounds for increasing the effectiveness of insecticides and pesticides.

The invention provides a completely new process route for synthesizing dexamethasone and series products thereof. The invention adopts 1, 4, 9, 16-tetraene-pregna-3, 20-diketone as the original material which is modified by 9, 11bits, 16, 17 bits and 21 bits so as to obtain the dexamethasone and the series products thereof such as dexamethasone acetate and dexamethasone sodium phosphate and the like. The process has the advantage that the invention adopts the existing intermediates of manufacturers as the original material; the route is simple; the materials are available; the use of expensive accessories is avoided; the yield and the cost are dramatically better than that of the prior methods used for synthesizing the dexamethasone and derivatives thereof; moreover, the adoption of the existing intermediates realizes the combined-line prodction of the betamethasone series products and the dexamethasone series products, thus greatly reducing the manufacturing cost and the industrial manufacturing condition.

A resist composition is provided comprising a (co)polymer comprising recurring units of acid labile group-substituted (meth)acrylic acid, styrenecarboxylic acid or vinylnaphthalenecarboxylic acid and / or recurring units having an acid labile group-substituted phenolic hydroxyl group, an acid generator, and a metal salt of carboxylic acid or a metal complex of β-diketone. Due to a high contrast of alkaline dissolution rate before and after exposure, high resolution, high sensitivity, and controlled acid diffusion rate, the composition forms a pattern with satisfactory profile and minimal LER.

The invention discloses an iridium complex phosphor material taking a phthalazine derivative as a ligand. The structure of the material is shown as formulas (I) and (II), wherein Ar represents aryl, substituted aryl, heterocycle aryl and substituted heterocycle aryl; R can be one of a halogen atom, alkyl, substituted alkyl, alkoxyl, aryloxy, an alkylthio group, arylthio, aromatic amino, aliphatic amino or a heterocyclic substituent; L^Y can be one of N-COOH, 8-hydroxyquinoline, beta-diketone, N^NH and the like; N^N can be bipyridyl, diquinoline, 1,10-phenanthroline, a derivative of the 1,10-phenanthroline and the like; and Z can be hexafluorophosphate and perchlorate. A dicyclic or ionic iridium complex phosphorescent electroluminescent device taking the phthalazine derivative as the ligand obtained with the preparation method has high internal and external quantum yields, high luminance and high stability. A dicyclic iridium complex is shown as a formula (I), i.e., (C^N)2Ir(L^Y); and an ionic iridium complex is shown as a formula (II), i.e., (C^N)2Ir(N^N)<+>Z<->.

A method for depositing a thin ruthenium (Ru) film on a substrate in a reaction chamber, comprising: step (i) of supplying at least one type of gas of a ruthenium precursor being a β-diketone-coordinated ruthenium complex and causing the gas to be adsorbed to the substrate in the reaction chamber; step (ii) of supplying a reducing gas into the reaction chamber and exciting the reducing gas, or supplying an excited reducing gas into the reaction chamber, in order to activate the ruthenium precursor adsorbed to the substrate; and step (iii) of repeating steps (i) and (ii) to form a thin ruthenium film on the substrate.

A photopolymerization initiator comprising (A) a photo acid-generating compound such as diaryliodonium salt (e.g., diphenyl iodonium, bis(p-chlorophenyl)iodonium, etc.), (B) a photo oxidation radical-generating compound such as diarylketone compound, alpha-diketone compound or ketocoumarin compound, and (C) a fused polycyclic aromatic compound such as 1,4-dimethylnaphthalene, 1-methylanthracene, 9-methylanthracene, 9,10-dimethylanthracene or 9,10-diethylanthracene. The photopolymerization initiator makes it possible to efficiently polymerize the cationically polymerizable monomer by the irradiation with visible light.

The invention discloses a composition containing HFC-161 and a stabilizer, wherein the stabilizer is selected from one or more of epoxy compound, nitro-compound, hindered amines, hindered phenols, secondary arylamines, beta-diketones, phosphite esters, salicylic acid esters, cinnamic acid esters, hydroxybenzophenones, hydroxybenzoic acids, hydroxylphenyl benzotriazoles, hydroxylphenyl triazines, oxanilides, formamidines, polyhydric alcohols, ortho-formates, organosulfur compounds, olefins, ethanol amines and fatty amines. The composition provided by the invention is capable of keeping a stable state in a long time under the coexistence of air or oxygen, and capable of being used as a heat transfer composition in the form of a liquid or a gas, a refrigerant, an aerosol propellant and the like.

The present invention provides atomic layer deposition systems and methods that include metal compounds with at least one β-diketiminate ligand. Such systems and methods can be useful for depositing metal-containing layers on substrates.

The present invention provides metal-containing compounds that include at least one β-diketiminate ligand, and methods of making and using the same. In certain embodiments, the metal-containing compounds include at least one β-diketiminate ligand with at least one fluorine-containing organic group as a substituent. In other certain embodiments, the metal-containing compounds include at least one β-diketiminate ligand with at least one aliphatic group as a substituent selected to have greater degrees of freedom than the corresponding substituent in the β-diketiminate ligands of certain metal-containing compounds known in the art. The compounds can be used to deposit metal-containing layers using vapor deposition methods. Vapor deposition systems including the compounds are also provided. Sources for β-diketiminate ligands are also provided.

Solid forms comprising 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed

A series of organometallic complexes and the singlet oxygen sensitization properties of these complexes are provided. Complexes with acetylacetonate ligands give singlet oxygen quantum yields near unity, whether exciting the ligand-based state or the lowest energy excited state (MLCT+3LC). The singlet oxygen quenching rates for these β-diketonate complexes are small, roughly three orders of magnitude slower than the corresponding phosphorescence quenching rate. Similar complexes were prepared with glycine or pyridine tethered to the Ir(III) center (i.e. (bsn)2Ir(gly) and (bt)2Ir(py)Cl, where gly=glycine, and py=pyridine). The glycine and pyridine derivatives give high singlet oxygen yields.

The present invention provides metal-containing compounds that include at least one β-diketiminate ligand, and methods of making and using the same. In some embodiments, the metal-containing compounds are homoleptic complexes that include unsymmetrical β-diketiminate ligands. In other embodiments, the metal-containing compounds are heteroleptic complexes including at least one β-diketiminate ligand. The compounds can be used to deposit metal-containing layers using vapor deposition methods. Vapor deposition systems including the compounds are also provided. Sources for β-diketiminate ligands are also provided.

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

The invention discloses a type of amino acid modified curcumin, a synthesis method thereof, and an application thereof. According to the invention, structural modification is carried out upon curcumin by using natural amino acid, such that 1-(4-hydroxy-3-methoxyphenyl)-7-(4-oxyacetyl amino carbobenzoxy-3-methoxyphenyl)-1,6-heptadiene-3,5-diketone which is represented by a general formula (I) is obtained. With an MTT method, evaluation is carried out upon the compound represented by the general formula (I) in the inhabitance of proliferation activities of four cells which are K562, H22, HL60 and S180. IC50 values of the compound represented by the general formula (I) in inhibiting the proliferations of the four tumor cells are calculated. As a result of experiments, with the compound represented by the general formula (I), proliferations of tumor cells can be substantially inhibited. The compound has excellent anti-tumor activity, and can be prepared into anti-tumor medicines.